Allonix Therapeutics
Biotechnology Research • 
Atlanta, Georgia, United States • 1-10 Employees
Company overview
| Headquarters | Atlanta, Georgia, United States |
| NAICS | 541714 |
| Founded | 2023 |
| Employees | 1-10 |
Key Contacts at Allonix Therapeutics
Eric Ortlund
Co-Founder
Aubrey Smith
Associate Director Of Operations
About Allonix Therapeutics
Company Overview: Allonix Therapeutics is developing first-in-class small molecule agonists of LRH-1, a nuclear receptor critical for maintaining intestinal immune homeostasis and epithelial renewal. Our approach aims to drive local steroid production in the gut to reduce inflammation and promote healing in IBD. Team: Our founders include Dr. Eric Ortlund, a leading expert in nuclear receptor pharmacology and chemical biology, and Dr. John Calvert, a specialist in preclinical IBD models and translational research. Together, they bring over a decade of experience in LRH-1 biology and drug development. The broader Allonix team brings deep industry expertise across R&D, operations, venture, and drug development—with veterans from large pharma, venture capital, and biotech startups, and leading scientists with decades of combined experience in LRH-1 biology, medicinal chemistry, CMC, and IBD models.
Allonix Therapeutics revenue & valuation
| Annual revenue | $769,995 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,500,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Allonix Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Allonix Therapeutics has never raised funding before.
Spain
Frequently asked questions
4.8
40,000 users
